Regular Aspirin Intake Reduces Risk Of Death From Prostrate Cancer

Men who have been treated for prostate cancer, either by having surgery or radiation, may benefit from taking aspirin continuously, says new research that features a researcher at UT Southwestern Medical Center.

Having aspirin is linked to a lower risk of death from prostate cancer, especially in males along with high risk disease, based on a multicenter study posted in today's issue of the Journal of Clinical Oncology. Dr. Choe, associate professor of radiation oncology at UT Southwestern, is first writer of the paper.

Preclinical studies have proven which typically aspirin along with other anticoagulation medicines may inhibit cancer development and metastasis, but clinical data are now limited previously. The research checked out almost 6,000 males in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) data source who had prostate cancer handled by having surgery or radiotherapy.

About 2,200 of the men concerned - 37 percent - were really obtaining anticoagulants. The possibility of death from prostate cancer appeared to be in contrast between those taking anticoagulants and those that were not.

"The outcomes from this study recommend that aspirin prevents the expansion of tumor cells in prostate cancer, especially in hazardous prostate cancer, for which we don't have an excellent therapy currently," Dr. Choe said. "But we are required to better understand the optimal utilization of aspirin before routinely advocating it to all prostate cancer affected individuals."